tbuckley/cabot-search huggingface dataset:
Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis?
Authors: D. H. A. Nguyen, P. T. Truong, M. Lesperance, C. Alexander, C. V. Walter, E. Hayashi, J. Christie, I. A. Olivotto
Journal: Journal of Clinical Oncology (2011)

89 Background: To determine whether locoregional treatment (LRT) of the primary tumor improves outcomes in patients with stage IV breast cancer at diagnosis. Methods: The study cohort comprised 733 women referred from 1996 to 2005 to a population-based cancer institution with clinical or pathologic M1 breast cancer at diagnosis. Patient, tumor, and treatment characteristics were compared between women who were treated with (n=378) and without LRT (n=355) of the primary tumor. Five-year Kaplan-Meier overall survival (OS) and locoregional progression-free survival (LRPFS) were compared between groups. Multivariable analysis to control for potential confounding factors was performed using Cox regression modeling. Results: LRT consisted of surgery alone in 67%, radiotherapy alone in 22%, and both in 11% of patients. LRT use was significantly associated with age &lt;50 years, ECOG performance status 0-1, T1-2 tumors, and N0-1 disease, (all p&lt;0.05). Subjects with less metastatic disease burden and those asymptomatic from the M1 disease were more likely to undergo LRT (p&lt;0.001). Systemic therapy was used in 92% and 85% of patients treated with vs. without LRT, respectively. Five-year OS rates in the LRT and no LRT cohorts were 21% vs 14% (p&lt;0.001). The 5-year LRPFS rates were 72% vs 46% (p&lt;0.001). Among 378 patients who underwent LRT, 5-year OS rates were higher in patients with age &lt;50, ECOG 0-1, ER positive disease, clear surgical margins, single M1 subsite, bone only metastases, and 1-3 metastatic lesions (all p&lt;0.003). Type of LRT (surgery vs radiotherapy vs both) and type of surgery (lumpectomy vs mastectomy) were not associated with 5-year OS (all p&gt;0.05). On multivariable analysis, LRT was associated with improved OS (hazard ratio 0.78, 95% confidence interval 0.64-0.94, p=0.009). Conclusions: LRT of the primary disease was associated with improved survival in women with stage IV breast cancer at diagnosis. Among subjects treated with LRT, the most favorable survival rates were observed in patients with young age, good performance status, ER-positive disease, clear resection margins and in those with distant disease limited to one subsite, bone only, or fewer than 4 metastatic lesions.
Elective bilateral risk-reducing mastectomy (BRRM) in patients (pts) without breast cancer (BC): Experience at Mastologica Lomas Breast Center in Mexico City.
Authors: E. R. Sanchez-Forgach, C. Sanchez Basurto
Journal: Journal of Clinical Oncology (2011)

235 Background: BRRM otherwise known as prophylactic or preventive mastectomy has increased in frequency due to patient (pt) and/or physician preference. Variables included indications, medical or pt initiative, efficacy, complications and degree of satisfaction. Methods: Retrospective review of cases of BRRM from 2005-2010. Pts. were divided by indications including high risk factors, specimen pathology, breast reconstructions technique, complications, patient satisfaction index, and pt status. Results: A total of 16 pts. had a BRRM either for medical recommendations due to high risk features (including history of first degree relatives with BC (2 pts were BRCA 1 positive) or premalignant pathology in previous biopsies) in 13 (81.25%) cases and 3 (18.75%) owing to personal issues i.e. cancerophobia.Reconstruction technique for BRRM included 12 (75%) subpectoralis implants, 1 (6.25%) tissue expanders and secondary implants, and one (6.25%) latissimus dorsi flap with implant. BRRM complications included diverse degrees of seroma , diverse degrees of nipple-areola complex necrosis, total breast necrosis in one pt. 3 (18.75%) pts. had atypical ductal hyperplasia, 1 of which was bilateral. No BC cases have been recorded to date. Satisfaction with procedure is good to excellent in 14 (87.5%). Conclusions: BRRM is a safe procedure. Indications include medical evaluation (premalignant disease, high risk profile), or patient preference. Satisfaction with procedure is high.
Dose Finding Trial of Yttrium 90 (90Y) Ibritumomab Tiuxetan with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).
Authors: Ian W. Flinn, Brad S. Kahl, Eric Frey, Jesus A. Bianco, Richard J. Hammes, Lynn S. Billing, Lode J. Swinnen, George Sgouros, Richard L. Wahl
Journal: Blood (2004)
Significance of a case-management-led, multidisciplinary team approach in the treatment of prostate cancer.
Authors: Matthew Helbert, Timothy Brand
Journal: Journal of Clinical Oncology (2012)

81 Background: Prostate cancer is the most commonly diagnosed non-skin malignancy within the Madigan Health System. Madigan recognized the burden of prostate cancer and began a process improvement initiative on June 1, 2009 to provide patient-focused multi-disciplinary counseling and consultative service to patients newly and previously diagnosed with prostate cancer. Methods: The multi-disciplinary team and Prostate Cancer Pathway are led by a RN Case Manager in collaboration with the Departments of Urology, Radiation Oncology and Hematology Oncology. Patients enrolled in the pathway are case managed in accordance with NCCN evidenced based guidelines and have access to all specialty services contained within Madigan, the U.S. Army Western Region Medical Command, and the Tricare referral network. Major program goals of the Prostate Cancer Pathway are to bolster patient surveillance to levels congruent with national evidenced based guidelines, and to promote efficient use of clinic time by selectively scheduling patients based on acuity. The aims of the pathway are primarily accomplished through case management. Results: Prior to the implementation of case management, prostate cancer patients averaged 3.3 appointments per annum. Per NCCN guidelines, the average number of annual visits is 2.8 during the initial 5 year post treatment phase. Upon completion of 18 consecutive months of case management, program metrics indicate that the average number prostate cancer visits decreased to 2.9 appointments per year. Concurrently, case management screening impacted scheduled visits; resulting in 485 avoided appointments for reasons of clinical stability and favorable patient reported quality of life indicators. As a result of enhanced access, the total number of post program deployment prostate cancer patients increased by approximately 15%. Conclusions: Initial identified metrics indicate that prostate cancer case management can considerably impact surveillance rates and clinic efficiency and may be disseminated to additional populations. The case management led model has recently been utilized to create a similar pathway to address testicular cancer within the Madigan Health System.
Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.
Authors: George Somlo, Paul Frankel, Ricardo Spielberger, Chatchada Karanes, Amrita Krishnan, Pablo Parker, Leslie Popplewell, Firoozeh Sahebi, Timothy Schultheiss, Neil Martin Kogut, David S. Snyder, Anthony Selwyn Stein, Stephen J. Forman, Jeffrey Wong
Journal: Blood (2012)
Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)
Authors: Uwe Platzbecker, Ulrich Germing, Katharina Götze, Philipp Kiewe, Thomas Wolff, Karin Mayer, Joerg Chromik, Markus Radsak, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie, Aristoteles Giagounidis
Journal: Blood (2016)
Prognostic factors in leiomyosarcoma (LMS): Does primary site influence outcome?
Authors: M. F. R. Harunal Rashid, W. S. Ong, M. Teo, M. H. Tan, L. S. S. Foo, Y. K. Lim, F. Chin, M. J. F. Lee, Z. C. Ho, R. Jeevan, J. W. K. Chia, L. Soh, D. Poon, R. H. H. Quek
Journal: Journal of Clinical Oncology (2011)

10095 Background: LMS is a narrowly defined subset of soft tissue sarcoma with heterogeneous clinical presentation. Recent reports suggest differences in treatment responses between uterine (uLMS) and extrauterine (euLMS) disease. We sought to identify prognostic factors in LMS patients (pts) and study the impact of primary site on clinical outcomes. Methods: Single centre retrospective study. 97 eligible LMS pts seen in our centre from 2002 - 2010 with complete medical records were identified from our sarcoma database of 790 pts. Results: Median follow-up was 20.7 months (mths), 51% of pts had uLMS. Although median age in uLMS and euLMS was similar (49 vs 54 yrs), uLMS was less common beyond 60 yrs (10% vs 38%, p=0.002). Surgical resection rates (92% vs 79%), adjuvant therapy use (56% vs 42%) and metastatic disease at diagnosis (25% vs 27%) were not significantly different between uLMS and euLMS respectively. Amongst pts who underwent resection of disease, more uLMS pts had negative surgical margins (90% vs 48%, p=0.004). More lung (81% vs 48%, p=0.009) but fewer liver metastases (13% vs 41%, p=0.019) were seen in uLMS vs euLMS respectively. 57% of metastatic pts received palliative chemotherapy, of whom 55% had an anthracycline-based regimen in first line. No significant difference in response rate to first line chemotherapy was seen between uLMS and euLMS (19% vs 29%, p=0.621). In univariate analysis of clinicopathologic factors for the overall cohort, metastatic disease at presentation (p<0.001) was associated with inferior overall survival (OS). For non-metastatic pts who had surgery, a positive surgical margin was associated with a trend towards inferior relapse free survival (RFS) (p=0.062) that did not translate into a difference in OS. Median RFS and OS was 26.8 mths and 40.5 mths respectively. Both RFS (29.7 mths vs 25.5 mths) and OS (50.9 mths and 33.5 mths) were numerically superior in uLMS vs euLMS. Conclusions: This study demonstrates interesting clinicopathologic differences between uLMS and euLMS. While primary LMS site did not significantly impact on survival outcomes in this heterogeneously treated cohort of pts, the 17 mth OS difference in favour of uLMS is noteworthy. Disease stage remains the most vital prognostic factor in LMS.
Synergistic potentiation of anti-tumor immunity with light-activated drug therapy and anti-CTLA4 antibody treatment.
Authors: E. Bromley, R. Waitz, S. Wang, J. P. Allison
Journal: Journal of Clinical Oncology (2011)

27 Background: Talaporfin sodium (TS) is a light-activated, locally cytoreductive drug in phase III clinical trials for several different cancers. It is activated intratumorally with a thin, flexible LED array. TS treatment has been shown in preclinical studies to activate CD8 + -dependent anti-tumor immunity in a model of metastatic breast cancer. Anti-CTLA4 antibody is an immunotherapy that acts by suppressing negative regulation of immune effectors. It has recently completed a successful phase III clinical trial in melanoma patients in which it was shown to prolong survival. TS and anti-CTLA4 antibody have great potential to synergistically reduce primary tumor burden and generate systemic anti-tumor immunity. Methods: This study examined combination treatment with these two therapies in a murine prostate cancer tumor model (C57BL/6 + TRAMP C2). A large, established tumor on the left side of each mouse was treated with light-activated TS (or light- only control). One day after treatment, mice were injected intradermally with 0.5 × 10 6 TRAMP C2 cells on the opposite flank. Anti-CTLA4 (or vehicle control) was given on days 1, 4, 7 and 10. Progression of the untreated tumor was measured. Results: Growth of untreated tumors was prevented or significantly delayed in 55% and 33% of combination-treated animals, respectively (n = 9). In addition, contralateral tumor growth was prevented in 1 of 9 animals given talaporfin sodium alone while another animal's tumor showed growth delay. None of the untreated controls or anti-CTLA4 only animals showed a similar response. Individual combination-treated mice with delayed tumor growth often showed an atypical tumor growth curve in which progression either tapered off or began to reverse between 30 and 40 days post treatment. Conclusions: Reduction of tumor using local treatment with a light-activated drug could potentiate the anti-tumor immune response resulting from anti-CTLA4 treatment and prevent growth of secondary tumors in a preclinical prostate cancer model. [Table: see text]
Visualizing viable Mycobacterium tuberculosis in sputum to monitor isolation measures
Authors: Benjamin Wyplosz, Faiza Mougari, May Al Rawi, Céline Baillon, Dhiba Marigot-Outtandy, Damien Le Dû, Mathilde Jachym, Vincent Hervé, Laurent Raskine, Emmanuelle Cambau
Journal: Journal of Infection (2016)
NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)
Authors: Abraham M Varghese, Dena Cohen, Christopher F.E. Pocock, Andy Rawstron, Walter M Gregory, Alex Smith, Emma Skinner, Anne Critchley, Donald Milligan, Claire E. Dearden, Helen McCarthy, Chris Fegan, George A Follows, Peter Hillmen
Journal: Blood (2010)
The utility of PET-CT in predicting malignant potential of GIST.
Authors: Kozo Yoshikawa, Mitsuo Shimada, Nobuhiro Kurita, Hirohiko Sato, Masanori Nishioka, Takashi Iwata, Shinya Morimoto, Tomohiko Miyatani, Masakazu Goto, Hideya Kashihara, Chie Mikami
Journal: Journal of Clinical Oncology (2012)

38 Background: The risk category of gastrointestinal stromal tumors (GIST) is usually determined by tumor size and mitotic count. Because of technical complexity and tumor heterogeneity in biopsy, accurate preoperative evaluation of malignant potential of GIST is very difficult. The aim of this study is to evaluate the utility of preoperative PET-CT examination for predicting the malignant potential of GIST. Methods: Ten patients with GIST who underwent preoperative PET-CT examination were enrolled. They were divided into two groups (low/intermediate-risk or high-risk) by risk category (tumor size, mitotic index). The relationships between the standardized uptake value (SUV) and GIST parameters including the size, mitotic index and Ki67 index were examined. Results: There was a significant correlation between the mitotic index and the SUV (p=0.029) but tumor size is not correlated with SUV. The SUV was significantly higher in the high-risk group (11.0 ± 3.04) than in the low/intermediate-risk group (2.1 ± 1.5). The Ki67 labeling index was also significantly higher in the high-risk group (8.63 ± 6.2) than in the low/intermediate-risk group (1.75 ± 0.52). There was a significant correlation between the Ki67 labeling index and the SUV (p=0.028). A mitotic index of 5/50 HPF was equivalent to an SUV of 4.3, and a Ki67 labeling index of 5 was equivalent to SUV of 6.3. SUV of 5 can predict the malignant potential between the high and low/intermediate risk. Conclusions: PET-CT can predict malignant potential. Cases with a high SUV, using a criterion of 5, might have malignant potential.
microRNA-126 Orchestrates a Stem Cell-like Program in AML and B-ALL and Can be Exploited to Dissect Disease Heterogeneity
Authors: Francesca Pavesi, Carolina Caserta, Silvia Nucera, Matteo Maria Naldini, Andrea Cosentino, Giacomo Desantis, Jose Garcia-Manteiga, Matteo Carrabba, Massimo Bernardi, Luca Vago, Fabio Ciceri, Bernhard Gentner
Journal: Blood (2016)
Long Term Outcomes of First Line Tyrosine Kinase Inhibitors for Chronic Phase Chronic Myeloid Leukemia: A Mixed-Treatment Comparison
Authors: Belal Firwana, Mohamad Bassam Sonbol, Maria Diab, Rim Hasan, Ibraheem Yousef, Archana Garipalli, Shahzad Raza, Aref Al-Kali, Donald Doll
Journal: Blood (2014)
Down-Regulation of Activin A by Lymphoma: A Possible Mechanism of Bone Marrow Involvement.
Authors: Michal Z. Haran, Reshmi Parameswaran, Edit Feldberg, Mina Fogel, Monica Huszar, Alain Berrebi, Mordechai Shtalrid, Lev Shvidel, Adrian Duek, Merav Leiba, Arnon Nagler, Dov Zipori
Journal: Blood (2005)
A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC).
Authors: M. Bilusic, J. L. Gulley, C. Heery, A. B. Apolo, P. M. Arlen, M. Rauckhorst, S. McMahon, W. L. Dahut, J. Schlom, R. A. Madan
Journal: Journal of Clinical Oncology (2011)

163 Background: PSA-TRICOM is a vector-based, therapeutic cancer vaccine regimen consisting of recombinant poxviruses containing the transgenes for prostate-specific antigen (PSA) and 3 T-cell co-stimulatory molecules (TRICOM). A previous randomized, placebo-controlled phase II study demonstrated an 8.5-month improvement in median survival (25.1 months for PSA-TRICOM group vs. 16.6 months for control group) in men with metastatic CRPC. Methods: This study is currently enrolling patients with non-metastatic CRPC on testosterone suppression therapy who have a rising PSA. Patients are stratified by PSA doubling time and randomized to androgen receptor antagonist alone (flutamide) or flutamide plus PSA-TRICOM. Flutamide is given at the standard dose of 400 mg TID while PSA-TRICOM is given by monthly subcutaneous injections. The primary endpoint of the study is time to treatment failure (TTF) which is defined as biochemical recurrence (PSA rise) or development of metastatic lesions on scans. Results: The first 26 patients enrolled are evaluated in this analysis. For flutamide alone (n = 13), the median age at enrollment was 64.7 years and median Gleason Score was 8. For flutamide + PSA-TRICOM (n = 13), the median age at enrollment was 67.1 years and median Gleason score was 8. Median time to progression is 223 days for Fluatmide + PSA- TRICOM (range 70-638) vs. 85 days for Flutamide alone (56-372). Progression for 11/12 flutamide alone patients and 9/10 fluatmide + PSA-TRICOM patients has been by PSA rise only. Conclusions: Preliminary evidence suggests improvement in time to treatment failure using combination of hormonal therapy with flutamide + PSA-TRICOM vaccine compared to fluatmide alone in patients with non-metastatic CRPC. This trial will continue to accrue a total of 62 patients and also will evaluate immunological responses. No significant financial relationships to disclose.
In Vitro Large-Scale Expansion of Unfractionated Mononucleated Cells of Human Umbilical Cord Blood: Investigation for Clinical-Grade Generation of Cord Blood Hematopoietic Cells.
Authors: Ping Mao, Huaxin Duan, Caixia Wang, Tingfen Deng, Changru Luo, Yanli Xu, Yuping Zhang
Journal: Blood (2009)
Biliary tract cancer: A large institutional experience.
Authors: Mairead Geraldine McNamara, Anne Horgan, Thomas Walter, Elizabeth McKeever, Trisha Min, Anne Riga, David W Hedley, Sean P Cleary, Steven Gallinger, Paul David Greig, Stefano Serra, Laura A. Dawson, Jennifer J. Knox
Journal: Journal of Clinical Oncology (2012)

4109 Background: Biliary tract cancers (BTCs) encompass both cholangiocarcinoma (CC), arising in intrahepatic, perihilar (klatskin), or distal biliary tree, ampulla of vater and gallbladder carcinoma (GBC). Prognosis is poor for majority of these patients (pts). Aim: To retrospectively review outcomes of pts, as practices/treatments evolve, who presented to a multidisciplinary team at tertiary referral center Princess Margaret Hospital, Toronto, with a diagnosis of BTC. Methods: 1057 pts were followed from 01/87 - 09/11. Complete demographics, performance status (PS), disease site, histological diagnosis, percentage receiving surgery with curative intent, chemotherapy (CT), radiotherapy (RT), recurrence patterns and overall survival (OS) were analyzed. Results: The cohort includes 549 (52%) males, PS of 0-1 in 850 (80%), 2-3 in 87 (8%) pts. A histological diagnosis of adenocarcinoma was confirmed in 885 (84%), 106 (10%) non diagnostic, 66 (6%) other. Definitive surgery was performed in 41% and adjuvant CT or concurrent CT/RT given in 20% and 8% respectively. CT or CT/RT was given for unresectable/metastatic disease in first line palliative setting in 395 (37%) and 18 pts (5%) respectively. Response to first line CT in GBC was 33% vs. 24% in CC (p=0.005) and med survival was 8.4 and 13.1 mo respectively (p=0.001). The OS for entire cohort of 1057 pts was 19.3 mo with survival for breakdown of tumor type, stage detailed in the table. At this time, 207 (20%) are still alive, 609 (58%) deceased, status unknown/pending in 241 (22%). Conclusions: This represents a large biliary cancer cohort with survival benchmarks obtained in modern era of multidisciplinary care. Different subsites clearly present at different stages and have different prognosis with treatments. Despite better responses for advanced disease on CT in GBC, survival was better in CC consistent with reported literature. Therapeutic advancement mandates finding additional drug options and appropriate adjuvant care. [Table: see text]
The Risk of Venous Thrombosis Related to Increase in Body Mass Index Is Mediated by Factor VIII Induced APC-Resistance.
Authors: Willem M Lijfering, Sverre C Christiansen, Inger-Anne Naess, Jens Hammerstrøm, Astrid van Hylckama Vlieg, Frits Rosendaal, Suzanne C Cannegieter
Journal: Blood (2009)
Predictors of outcome using salvage androgen deprivation therapy after radical prostatectomy.
Authors: M. K. Tollefson, E. J. Bergstralh, L. J. Rangel, R. J. Karnes
Journal: Journal of Clinical Oncology (2011)

74 Background: Nearly all men that experience recurrence of prostate cancer after radical prostatectomy are placed on salvage androgen deprivation therapy (sADT) in an attempt to control the disease. Yet, little is known regarding the efficacy of the treatment, the therapeutic duration or the predictors of treatment failure. Therefore, we examined our experience with sADT after radical prostatectomy in a cohort of patients with no evidence of systemic disease. Methods: We identified 1,373 patients that were treated with sADT after radical prostatectomy prior to the development of systemic disease. Clinical and pathologic variables predicting systemic progression and cancer death were evaluated using the Kaplan-Meier method and compared using the log rank test. Multivariate Cox proportional hazard regression models were used to analyze the impact of these variables on disease progression and survival. Results: Patients were treated with sADT at a median of 4.2 years after surgery. The median PSA at initiation of sADT was 1.6 ng/mL. The majority (1,234, 90%) of patients had a calculable PSA doubling time prior to the initiation of sADT. 275 patients (20.0%) experienced systemic progression at a median of 3.1 years after the start of sADT. 175 patients (12.7%) died of prostate cancer at a median of 4.7 years after the start of sADT. Factors that predicted disease progression after sADT on multivariate analysis included either neoadjuvant or adjuvant ADT (HR - 2.0, p&lt;0.0001), increasing pathologic Gleason Score (HR - 1.18, p=0.009), increasing pathologic stage (HR - 1.3, p&lt;0.0001), PSA at start of sADT (HR - 1.3, p&lt;0.0001) and PSA doubling time (1.65, p&lt;0.0001). Conclusions: Most men treated with sADT after radical prostatectomy prior to the development of systemic progression experience a lengthy disease-free interval. Multivariate predictors of treatment failure include prior adjuvant or neoadjuvant ADT, pathologic Gleason Score, pathologic stage, PSA level at initiation of sADT and PSA doubling time before sADT. No significant financial relationships to disclose.